LCTXLineage Cell Therapeutics, ...

NYSE lineagecell.com


$ 1.06 $ -0.08 (-7.08 %)    

Thursday, 02-May-2024 15:59:42 EDT
QQQ $ 429.07 $ 5.38 (1.28 %)
DIA $ 382.31 $ 3.34 (0.88 %)
SPY $ 505.01 $ 4.68 (0.94 %)
TLT $ 88.87 $ 0.38 (0.43 %)
GLD $ 213.12 $ -0.66 (-0.31 %)
$ 1.05
$ 1.08
$ 0.00 x 0
$ 0.00 x 0
$ 1.04 - $ 1.11
$ 0.84 - $ 1.61
1,837,068
na
181.3M
$ 1.01
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-07-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-09-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-10-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-11-2021 12-31-2020 10-K
14 11-04-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-12-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 03-14-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-02-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-15-2018 12-31-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-09-2017 06-30-2017 10-Q
28 05-10-2017 03-31-2017 10-Q
29 03-16-2017 12-31-2016 10-K
30 11-04-2016 09-30-2016 10-Q
31 08-09-2016 06-30-2016 10-Q
32 05-10-2016 03-31-2016 10-Q
33 03-15-2016 12-31-2015 10-K
34 11-09-2015 09-30-2015 10-Q
35 08-10-2015 06-30-2015 10-Q
36 05-08-2015 03-31-2015 10-Q
37 03-11-2015 12-31-2014 10-K
38 11-07-2014 09-30-2014 10-Q
39 08-11-2014 06-30-2014 10-Q
40 05-12-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lineage-cell-therapeutics-inc-may-offer-and-sell-common-shares-of-up-to-40m-from-time-to-time-through-or-to-b-riley

- SEC Filing

 lineage-cell-therapeutics-entered-into-sales-agreement-with-b-riley-securities-effective-as-of-march-18-controlled-equity-offering-sales-agreement-between-co-and-cantor-fitzgerald--co-was-terminated-on-march-12-received-written-correspondence-from-us-fda-regarding-its-ind-as-amended-for-opc1-per-correspondence-fda-advised-that-company-not-initiate-proposed-clinical-study-until-it-has-received-fda-feedback-fda-anticipates-providing-feedback-by-april-26-2024

-SEC Filing

 lineage-cell-therapeutics-inc-announces-rg6501-opregen-phase-12a-clinical-study-24-month-results-to-be-featured-at-2024-retinal-cell--gene-therapy-innovation-summit

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ce...

 lineage-cell-therapeutics-announces-opregen-preclinical-engraftment-results-to-be-presented-at-2024-association-for-research-in-vision-and-ophthalmology-meeting

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ce...

 hc-wainwright--co-reiterates-buy-on-lineage-cell-therapeutics-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $...

 lineage-cell-therapeutics-q4-2023-gaap-eps-0030-beats-0040-estimate-sales-2100m-beat-1310m-estimate

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.030) per share which beat the analyst consensus estimate...

 earnings-scheduled-for-march-7-2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...

 hc-wainwright--co-reiterates-buy-on-lineage-cell-therapeutics-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $...

 lineage-cell-therapeutics-announces-14m-million-registered-direct-offering

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ce...

 cantor-fitzgerald-reiterates-overweight-on-lineage-cell-therapeutics-maintains-6-price-target

Cantor Fitzgerald analyst Kristen Kluska reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Overweight and maintains $6...

 lineage-cell-therapeutics-inc-announces-rg6501-phase-12a-results-will-be-featured-at-2024-angiogenesis-exudation-and-degeneration-meeting-in-presentation-by-allen-ho-md-facs-fasrs

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ce...

 lineage-cell-therapeutics-longeveron-and-2-other-stocks-under-2-insiders-are-buying

The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their con...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION